國立虎尾科技大學 |

New Approaches to Drug Discovery

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	New Approaches to Drug Discovery/ edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch.
其他作者:	Nielsch, Ulrich.
面頁冊數:	VIII, 341 p. 100 illus., 63 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmacology. -
電子資源:	https://doi.org/10.1007/978-3-319-28914-4
ISBN:	9783319289144

New Approaches to Drug Discovery
New Approaches to Drug Discovery[electronic resource] /edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch. - 1st ed. 2016. - VIII, 341 p. 100 illus., 63 illus. in color.online resource. - Handbook of Experimental Pharmacology,2320171-2004 ;. - Handbook of Experimental Pharmacology,224.

Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.

This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.

ISBN: 9783319289144

Standard No.: 10.1007/978-3-319-28914-4doiSubjects--Topical Terms:

583819
Pharmacology.

LC Class. No.: RM1-950

Dewey Class. No.: 615

New Approaches to Drug Discovery
LDR:03161nam a22004095i 4500 001 971242
003 DE-He213
005 20200629164154.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319289144 $9 978-3-319-28914-4
024 7 $a 10.1007/978-3-319-28914-4 $2 doi
035 $a 978-3-319-28914-4
050 4 $a RM1-950
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615 $2 23
245 1 0 $a New Approaches to Drug Discovery $h [electronic resource] / $c edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a VIII, 341 p. 100 illus., 63 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Handbook of Experimental Pharmacology, $x 0171-2004 ; $v 232
505 0 $a Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
520 $a This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
650 0 $a Pharmacology. $3 583819
650 0 $a Pharmacy. $3 582411
650 0 $a Medical biochemistry. $3 1254555
650 0 $a Metabolism. $3 581368
650 1 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Drug Safety and Pharmacovigilance. $3 1064651
650 2 4 $a Medical Biochemistry. $3 668897
650 2 4 $a Metabolomics. $3 882386
700 1 $a Nielsch, Ulrich. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1106485
700 1 $a Fuhrmann, Ulrike. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1106486
700 1 $a Jaroch, Stefan. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1106487
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319289120
776 0 8 $i Printed edition: $z 9783319289137
776 0 8 $i Printed edition: $z 9783319804552
830 0 $a Handbook of Experimental Pharmacology, $x 0171-2004 ; $v 224 $3 1254015
856 4 0 $u https://doi.org/10.1007/978-3-319-28914-4
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)